Wanbury Limited announced that its Andhra Pradesh API manufacturing site in Tanuku was named "Best Employer" by the State Government, while its Maharashtra facility in Patalganga received a "Certificate of Excellence" for safety performance.

The recognition highlights the company's focus on environment, health, and safety (EHS) standards alongside Good Manufacturing Practice (GMP) compliance. The Patalganga facility secured the safety award from the National Safety Council for the third consecutive year, underscoring consistent operational discipline.

Facility recognitions

The awards were presented to specific manufacturing units based on distinct criteria:

• Patalganga, Maharashtra: Received the "Certificate of Excellence" from the National Safety Council for outstanding safety performance.
• Tanuku, Andhra Pradesh: Named "Best Employer" by the State Government for exemplary employee practices and workplace culture.

Both facilities are USFDA and EUGMP approved, serving as key hubs for Wanbury's API exports to over 50 countries and domestic formulation needs.

Management commentary

Mohan Rayana, Director of Wanbury, stated that people and their safety are central to the company's operations. He noted that these awards recognize the dedication of the Tanuku and Patalganga teams to maintaining a safe, compliant, and rewarding workplace. The company affirmed its commitment to raising standards on employee welfare and safety across all sites.

About the company

Established in 1988, Wanbury operates in the API global market and domestic branded formulations. Its product portfolio includes antidiabetic, antidepressant, pain management, and anti-inflammatory drugs. The company maintains a Pan-India formulation presence with clients including leading global generic players.

Wanbury received 9 "No DMF Deficiency" letters from the US Food and Drug Administration (USFDA) for Metformin HCL, while also expanding its Metformin business into Saudi Arabia and Mexico.

USFDA recognition for Metformin HCL

The 9 "No DMF Deficiency" letters from the USFDA represent a regulatory acknowledgment that Wanbury's Drug Master File (DMF) submissions for Metformin HCL meet the required standards without any deficiencies. This recognition covers multiple filings, underscoring the company's compliance standing with one of the world's most stringent drug regulatory authorities. The company highlights this as evidence of strong regulatory filings quality, which creates new business opportunities in the US market.

Geographic expansion of Metformin business

Alongside the USFDA development, Wanbury has expanded its Metformin business into two new markets: Saudi Arabia and Mexico. The following table summarises the key highlights of these developments:

Key highlights

• Wanbury received 9 "No DMF Deficiency" letters from the USFDA for Metformin HCL.
• The letters indicate that the company's DMF submissions met USFDA standards without deficiencies.
• The company expanded its Metformin business into Saudi Arabia and Mexico.
• These developments reflect Wanbury's focus on strengthening its regulatory credentials and broadening its international market presence for Metformin HCL.